An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study finds that the insulin-sensitiser pioglitazone, as a treatment for non-alcoholic fatty liver disease (NAFLD), shows some improvements in liver histology and other parameters but the newer agents, the glucagon-like peptide-1 analogues, may be more worthy of future trials. The review suggests that the non-alcoholic steatohepatitis stage of NAFLD is most in need of drug trials.
1 Warwick Evidence, Health Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, UK
2 Hasenheide 67, Berlin, Germany
3 University of Glasgow, Glasgow, UK
4 NHS Highland, Inverness, UK
5 Aberdeen Royal Infirmary, Aberdeen, UK
* Corresponding author Email: n.r.waugh@abdn.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document